Series A
Imago BioSciences, a therapeutics company, has raised $26.5 million in Series A financing led by Clarus Ventures. Frazier Healthcare, Amgen Ventures, and Merck Research Labs Venture Fund also participated in the round. “Imago BioSciences is extremely gratified with the makeup of this investment syndicate,” said Hugh Young Rienhoff, M.D., CEO at Imago BioSciences. “They comprise a group of experienced financial and strategic investors who provide financial support to progress our clinical development program in a direction important to patients and their physicians.”
Funding
Butterfly Network has raised $100 million to manufacture handheld medical imaging devices. The company’s device aims to make ultrasounds and MRIs easier and cheaper to conduct. Aeris Capital and Jonathan Rothberg were among the investors into the company, which aims to launch the device within 18 months. “Spending 18 percent of our GDP or $10,000 per person, per year, on healthcare is unsustainable, and out of touch with the needs of the rest of the world,” said Dr. Rothberg. “At 4Combinator, our mission is to democratize healthcare by launching companies, building devices, and combining advances in biology, semiconductors, and AI”. We built Butterfly to transform the way we image the body and perform surgery”.
Quanta Fluid Solutions, which provides advanced hemodialysis systems, has raised £27 million ($43 million). The investment round was led by ALIAD with participation from Seventure Partners and existing investors Wellington Partners, Seroba Kernel, NBGI Ventures, b-to-v Partners and IMI. The company will use the funds for the development of SC+, it’s portable compact dialysis system. “This funding will support our activities as we progress SC+ towards clinical introduction and subsequent commercial launch. We are delighted to welcome our new investors ALIAD and Seventure Partners, who share our vision of improving renal care for patients and healthcare professionals,” said John E. Milad, Chief Executive Officer of Quanta.